Share Prices & Company Research

Stockbroking

Astrazeneca Plc

Current Price 10194.00p Bid 10192.00p Ask 10246.00p Change -1.20%
Last Updated: 28/02/2024 22:57. Prices delayed by at least 15 minutes.
Call 0113 243 6941 or search for your local office

Company Overview

A world-leading pharmaceutical group, AstraZeneca was created in 1999 via the merger of Sweden's Astra and the UK's Zeneca, which had been demerged from chemicals group ICI in 1993. About half of its total sales are generated from the US, with over a third of revenues coming from its gastrointestinal treatments such as Prilosec (Losec) and Nexium.

Financial Highlights Year Ended 31/12/2019

Revenue
£24,384.00m
Operating Profit/Loss
£2,924.00m
Dividend yield (%)
2.80
Total dividend for year
$2.8000
Dividend cover
0.37
P/E Ratio
98.20

Key Personnel

Mr Pascal Soriot
CEO and Executive director
Dr Aradhana Sarin
CFO & Executive Director
Dr Euan Ashley
Non-Executive Director
Mr Andreas Rummelt
Non-Executive Director
Mr Marcus Wallenberg
Non-Executive Director
Mr Michel Demare
Non-Executive Director
Mr Philip A J Broadley
Non-Executive Director
Mr Tony Mok
Non-Executive Director
Mrs Deborah DiSanzo
Non-Executive Director
Mrs Nazneen Rahman
Non-Executive Director
Mrs Sheri McCoy
Non-Executive Director
Ms Anna Manz
Non-Executive Director
Ms Diana Layfield
Non-Executive Director

Stock Details

EPIC
AZNL
ISIN
GB0009895292
Shares in Issue
1,264.16m
Market cap
£128,868.75m

Analyst Views (10)

Strong Buy
 
0%
Buy
 
70.00%
Hold
 
10.00%
Sell
 
20.00%
Strong Sell
 
0%
This information is provided by Web Financial Group (UK) Limited. It is subject to change without notice and doesn't reflect the views held by Redmayne Bentley and is not advice.

Price Summary

Mid Price
10,194.00p
Bid Price
10,192.00p
Ask Price
10,246.00p
Volume
318,166
Change Today
-124.00p
% Change Today
-1.20%
Open
10,310.00p
Previous Close
10,194.00p
Intraday High
10,340.00p
Intraday Low
10,185.00p
52 Week High
12,292.00p
52 Week Low
9,521.00p
52 week high and low figures quoted above are calculated from intraday price data.

Intra-Day Chart

News

AstraZeneca's blood-disorder drug recommended for EU approval 26/02/2024 07:22:47 AstraZeneca acquires US-based biopharmaceutical company 20/02/2024 10:29:48 AstraZeneca's Tagrisso gains FDA approval 19/02/2024 08:03:08 Barclays sees "compelling" entry point at AstraZeneca after recent falls 12/02/2024 09:12:24 London close: Stocks slip as US jobless claims fall 08/02/2024 14:42:47 AstraZeneca shares slip as Q4 profits miss forecasts 08/02/2024 07:58:40 London close: Stocks finish lower as wage growth eases 16/01/2024 16:17:12 UBS downgrades AstraZeneca to 'sell' 16/01/2024 08:15:37 Jefferies upgrades GSK to 'buy', cuts AstraZeneca to 'hold' 03/01/2024 11:07:01 AstraZeneca to buy Gracell Technologies for $1.2bn 27/12/2023 07:02:54 AstraZeneca gets FDA green light for nerve disease treatment 22/12/2023 07:17:04 AstraZeneca to buy US vaccine maker Icosavax for up to $1.1bn 12/12/2023 07:16:41 AstraZeneca calls off two phase III trials into hyperkalaemia treatment 01/12/2023 08:01:26 AstraZeneca gets US approval for breast cancer treatment 17/11/2023 07:16:57 AstraZeneca's latest lung cancer trial fails its primary endpoint 14/11/2023 09:22:35 AstraZeneca hikes guidance after strong third quarter 09/11/2023 07:18:45 AstraZeneca invests $220m in French gene-editing group Cellectis 01/11/2023 07:33:31 AstraZeneca agrees to settle most Nexium, Prilosec claims 03/10/2023 07:24:37 AstraZeneca reports positive findings from breast cancer threatment trial 22/09/2023 07:27:29 AstraZeneca working with FDA on finer details of Ultomiris treatment 06/09/2023 07:45:52 AstraZeneca posts strong first half despite Covid drug weakness 28/07/2023 07:04:44 AstraZeneca, Sanofi infant respiratory treatment gets US approval 18/07/2023 08:10:05 AstraZeneca reveals mixed interim findings in lung cancer trial 03/07/2023 07:57:23 AstraZeneca planning spinoff of China business - report 19/06/2023 09:28:26 AstraZeneca gets new FDA RSV approval, partners with Quell 09/06/2023 10:09:24

Income Statement

Year End Date
31 Dec 2019
31 Dec 2018
 
$ (M)
$ (M)
Continuing Operations
Revenue
24,384.00
22,090.00
Operating Profit/Loss
2,924.00
3,387.00
Net Interest
-1,260.00
-1.28
Pre-Tax Profit
1,548.00
1,993.00
Profit After Tax from continuing operations
1,227.00
2,050.00
Discontinued Operations
Profit After Tax
n/a
n/a
Profit/Loss for the Year
1,227.00
2,050.00
Attributable to:
Equity Holders of Parent Company
1,335.00
2,155.00
Minority Interests
-108.00
-105.00
Total Dividend Paid
$2.8000
$2.8000
Retained Profit/(Loss) for the Financial Year
n/a
n/a

Earnings per Share

Year End Date
31 Dec 2019
31 Dec 2018
Basic
103.00c
170.00c
Diluted
103.00c
170.00c
Adjusted
103.00c
170.00c
Dividend per Share
$2.8000
$2.8000

Assets

Year End Date
31 Dec 2019
31 Dec 2018
 
$ (M)
$ (M)
Non-Current Assets
Property, Plant & Equipment
8,335.00
7,421.00
Intangible Assets
32,501.00
33,666.00
Investment Properties
n/a
n/a
Investments
1,459.00
922.00
Other Financial Assets
n/a
n/a
Other Non-Current Assets
3,519.00
3,051.00
Current Assets
Inventories
3,193.00
2,890.00
Trade & Other Receivables
6,046.00
5,781.00
Cash at Bank & In Hand
5,369.00
4,831.00
Current Asset Investments
n/a
n/a
Other Current Assets
955.00
2,089.00
Other Assets
n/a
n/a
Total Assets
61,377.00
60,651.00

Liabilities

Year End Date
31 Dec 2019
31 Dec 2018
 
$ (M)
$ (M)
Current Liabilities
Borrowings
2,010.00
1,754.00
Other Current Liabilities
16,107.00
14,538.00
Total Current Liabilities
18,117.00
16,292.00
Non-Current Liabilities
Borrowings
16,217.00
17,359.00
Provisions
3,331.00
3,671.00
Other Non-Current Liabilities
9,116.00
9,285.00
Total Non-Current Liabilities
28,664.00
30,315.00
Other Liabilities
n/a
n/a
Total Liabilities
46,781.00
46,607.00

Net Assets

Year End Date
31 Dec 2019
31 Dec 2018
 
$ (M)
$ (M)
Net Assets
14,596.00
14,044.00

Capital & Reserves

Year End Date
31 Dec 2019
31 Dec 2018
 
$ (M)
$ (M)
Share Capital
328.00
317.00
Share Premium Account
7,941.00
4,427.00
Other Reserves
2,046.00
2,041.00
Retained Earnings
2,812.00
5,683.00
Shareholders Funds
13,127.00
12,468.00
Minority Interests/Other Equity
1,469.00
1,576.00
Total Equity
14,596.00
14,044.00

Dividend History

Type
Ex-Dividend Date
Payment Date
Payment
2nd Interim
22 Feb 2024
25 Mar 2024
197.00¢
1st Interim
10 Aug 2023
11 Sep 2023
93.00¢
2nd Interim
23 Feb 2023
27 Mar 2023
197.00¢
1st Interim
11 Aug 2022
12 Sep 2022
93.00¢
2nd Interim
24 Feb 2022
28 Mar 2022
197.00¢
1st Interim
12 Aug 2021
13 Sep 2021
90.00¢
2nd Interim
25 Feb 2021
29 Mar 2021
190.00¢
1st Interim
13 Aug 2020
14 Sep 2020
90.00¢
2nd Interim
27 Feb 2020
30 Mar 2020
190.00¢
1st Interim
08 Aug 2019
09 Sep 2019
90.00¢
2nd Interim
28 Feb 2019
27 Mar 2019
190.00¢
1st Interim
09 Aug 2018
10 Sep 2018
90.00¢
2nd Interim
15 Feb 2018
19 Mar 2018
190.00¢
1st Interim
10 Aug 2017
11 Sep 2017
90.00¢
2nd Interim
16 Feb 2017
20 Mar 2017
190.00¢
1st Interim
11 Aug 2016
12 Sep 2016
90.00¢
2nd Interim
17 Feb 2016
21 Mar 2016
190.00¢
1st Interim
13 Aug 2015
14 Sep 2015
90.00¢
Final
03 Feb 2010
15 Mar 2010
171.00¢
Final
03 Feb 2010
15 Mar 2010
171.00¢
Final
03 Feb 2010
15 Mar 2010
171.00¢
Final
03 Feb 2010
15 Mar 2010
171.00¢
Interim
05 Aug 2009
14 Sep 2009
59.00¢
Interim
05 Aug 2009
14 Sep 2009
59.00¢
Interim
05 Aug 2009
14 Sep 2009
59.00¢
Interim
05 Aug 2009
14 Sep 2009
59.00¢

Dividend Metrics

Year End Date
31 Dec 2019
31 Dec 2018
Dividend growth
n/a%
n/a%
Dividend yield
2.80%
3.60%
Dividend cover
0.37
0.61


Cboe Global Markets® is a registered trade mark of Cboe Global Markets, Inc., a company incorporated in the United States of America with registered address at 400 South LaSalle Street, Chicago, IL 60605, USA. Cboe shall own any and all rights including without limitation Intellectual Property rights and any and all goodwill arising directly or indirectly out of the Recipient’s use of the “Cboe Global Markets®”, “Cboe®” and “Bats®”” trademarks. Neither Cboe nor its licensors accept any liability for any errors or omissions in the Cboe Europe Indices or underlying data. No further distribution of Cboe Europe data is permitted without Cboe’s express written consent.

The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.